ESC-HFA 2024: Late-Breaking Science Video Collection
Published: 14 May 2024
-
Views:
1067
-
Likes:
7
-
Views:
1067
-
Likes:
7
-
Up Next -
5m 24sPart 2 | Session 4 Timing of Cardio-Kidney Protection with SGLT2i -
2m 54s -
4m 46s -
4m 40sPart 2 | Session 7 FINE-HEART: Design & Baseline Characteristics -
11m 58sPart 2 | Session 8 HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
-
15m 26sPart 1 | Session 1 HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie Harriette Van Spall, Mark Petrie
-
10m 15sPart 1 | Session 2 Late-Breaker Discussion: The TITRATE-HF Study Harriette Van Spall, Jasper J Brugts
-
12m 4sPart 1 | Session 3 Late-Breaker Discussion: Insights from the STEP-HFpEF Harriette Van Spall, Mikhail Kosiborod
-
8m 37sPart 1 | Session 4 Late-Breaker Discussion: Findings from PACT-HF Harriette Van Spall, Tauben Averbuch
-
2m 45sPart 2 | Session 1 Remote Patient Monitoring for Patients With Heart Failure: TELESAT Nicolas Girerd
-
5m 3sPart 2 | Session 2 Cordella PA Sensor System in NYHA Class III HF Patients: PROACTIVE-HF Michael Kiernan
Overview
Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Association’s annual congress, Heart Failure 2024.
Dive deep into novel data with in-depth and critical discussions led by Late-breaker host Dr Harriette Van Spall and her expert guests.
For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators.
More from this programme
Part 1
Late-breaker Discussions with Dr Van Spall
Part 2
Expert Interviews
About the episode
HFA 24 - Dr Finn Gustafsson (Rigshospitalet, DK) joined us onsite at the Heart Failure Association Congress to discuss the findings from a subanalysis of the ARIES HeartMate 3 study (NCT04069156).
ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two different antithrombotic regimens. One treatment group received a Vitamin K antagonist, whereas another group received a vitamin K antagonist with placebo. Findings from AHA 23 showed that the omission of aspirin from an antithrombotic regimen including a VKA in advanced heart failure patients with a left ventricular assist device (LVAD) demonstrated non-inferiority when compared to a regimen that included aspirin.
This subanalysis investigated the patients with a guideline-based prior indication for aspirin in the trial, including those who had undergone PCI or CABG, or had peripheral vascular disease or stroke. This population comprised 41% of the 628 patients randomized in the study. The key findings showed that the primary endpoint of the incidence of death or haemocompatibility-related adverse event within the first 12 months was no different between patients with prior indication to aspirin as compared to those with no indication for aspirin.
Interview Questions:
- What is the importance of ARIES HM3?
- What was your patient population and study design?
- What are the key findings?
- How do these findings add to those revealed at AHA?
- What are your take-home messages?
- What are the remaining questions?
- What are the next steps?
Recorded onsite at HFA 24, Lisbon.
Support: This is an independent interview conducted by Radcliffe Cardiology.
Faculty Biographies
Finn Gustafsson
Professor of Cardiology
Finn Gustafsson, MD, PhD, DMSci, is a professor of cardiology at the University of Copenhagen and medical director of the advanced heart failure, transplantation and MCS program at Rigshospitalet in Copenhagen, Denmark. His clinical training in cardiology was conducted in Denmark and Canada. His research interests include several aspects of heart failure pathophysiology and management. He is an author of more than 300 peer reviewed articles in international scientific journals and several book chapters. Prof Gustafsson serves on the steering committee of several international clinical trials and registries within the field of advanced heart failure and HFpEF. He has served as an associate editor for several cardiology journals, including International Journal of Cardiology, Circulation: Heart Failure and European Journal of Heart Failure.
Comments